Amvuttra Approval: Alnylam’s Treatment for ATTR-CM
New Drug Offers hope for Rare Heart Condition as UK Approves Amvuttra
Table of Contents
London, UK – A significant breakthrough has been announced for individuals battling transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and perhaps fatal disease affecting the heart muscle. The UK’s Medicines and healthcare products Regulatory Agency (MHRA) has authorised Amvuttra (patisiran), a novel treatment that offers a new lifeline to patients suffering from this debilitating condition.
Understanding ATTR-CM: A Growing Concern
ATTR-CM arises when misfolded transthyretin (TTR) protein accumulates within the heart, leading to irreversible cardiovascular damage and severe health complications. This progressive disease can significantly impact a patient’s quality of life and,if left untreated,can be fatal.
There are two primary forms of ATTR-CM:
Wild-type ATTR-CM: This form is closely linked to the ageing process and most commonly affects individuals over the age of 50.
Hereditary ATTR-CM: This genetic form is passed down through families and is observed to be more prevalent within communities of African ancestry.
Amvuttra: A Promising New Treatment Option
The MHRA’s decision to authorise Amvuttra for wild-type or hereditary ATTR-CM is underpinned by compelling data from the late-stage HELIOS-B study. This pivotal trial demonstrated that Amvuttra was associated wiht significant reductions in both mortality and cardiovascular events among patients diagnosed with ATTR-CM.
Beyond these critical survival benefits, the study also highlighted Amvuttra’s ability to preserve functional status and enhance the quality of life for patients.Importantly, these positive effects were observed consistently across all patient subgroups, including those who were also receiving a concomitant TTR stabiliser.
Expert Endorsement and Patient Impact
Dr. Marianna Fontana,an investigator in the HELIOS-B study,expressed her enthusiasm for the drug’s availability. “As a physician, it’s a privilege to see a treatment that showed the potential to significantly improve outcomes in clinical trials now becoming available in practice – offering a new option for people living with this rapidly progressive disease,” she stated.
Amvuttra is administered as a subcutaneous injection, given once every three months. It can be administered by a healthcare professional or self-administered by patients, offering flexibility and convenience. The drug is designed to work by targeting the body’s natural systems to reduce TTR production at its source, thereby helping to slow the accumulation of harmful amyloid deposits.
Expanding Access and Future Outlook
This expanded indication marks a significant milestone for Alnylam Pharmaceuticals, the company behind Amvuttra. The drug is already approved by the MHRA for treating hereditary TTR-mediated ATTR amyloidosis in adults experiencing stage 1 or stage 2 polyneuropathy.
Phil Davey, contry manager for Alnylam Pharmaceuticals, UK and Ireland, commented on the declaration: “This announcement is a significant step forward for people living with ATTR-CM and a moment of immense pride for Alnylam. Since 2023, Amvuttra has been available in the UK for ATTR amyloidosis patients with polyneuropathy symptoms, and this expanded indication enables us to address the needs of a much broader group of people living with the disease.”
Alnylam has expressed its commitment to working collaboratively with the NHS to ensure prompt access to Amvuttra for all eligible patients across the United Kingdom. This advancement offers renewed hope and a tangible treatment option for individuals and families affected by ATTR-CM.